GAITHERSBURG, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee. On March 1, 2024, the Company issued to this employee an option to purchase 375,000 shares of the Company’s common stock with an exercise price of $0.69, the closing trading price of the...